DEXCOM INC
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
DXCM$79.92-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets (unaudited) as of and
DexCom, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
| (In millions, except share and par value data) | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,118.2 | $917.7 |
| Short-term marketable securities | 1,297.0 | 1,081.0 |
| Accounts receivable, net | 1,088.6 | 1,216.1 |
| Inventory | 693.6 | 629.1 |
| Prepaid and other current assets | 134.3 | 189.4 |
| Total current assets | 4,331.7 | 4,033.3 |
| Property and equipment, net | 1,559.7 | 1,559.9 |
| Operating lease right-of-use assets | 73.1 | 77.4 |
| Goodwill | 24.2 | 24.2 |
| Intangibles, net | 62.6 | 70.8 |
| Deferred tax assets | 296.1 | 295.6 |
| Other assets | 285.9 | 278.7 |
| Total assets | $6,633.3 | $6,339.9 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $2,073.9 | $1,944.0 |
| Accrued payroll and related expenses | 121.8 | 169.2 |
| Short-term operating lease liabilities | 20.5 | 21.6 |
| Other current liabilities | 7.6 | 7.7 |
| Total current liabilities | 2,223.8 | 2,142.5 |
| Long-term senior convertible notes | 1,241.8 | 1,240.9 |
| Long-term operating lease liabilities | 69.0 | 73.4 |
| Other long-term liabilities | 141.8 | 137.1 |
| Total liabilities | 3,676.4 | 3,593.9 |
| Commitments and contingencies (Note 5) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value, 800.0 million shares authorized; 412.3 million and 385.9 million shares issued and outstanding, respectively, at March 31, 2026; and 410.7 million and 384.8 million shares issued and outstanding, respectively, at December 31, 2025 | 0.4 | 0.4 |
| Additional paid-in capital | 2,337.5 | 2,281.5 |
| Accumulated other comprehensive income | 106.2 | 115.0 |
| Retained earnings | 2,633.4 | 2,433.9 |
| Treasury stock, at cost; 26.4 million shares at March 31, 2026 and 25.9 million shares at December 31, 2025 | (2,120.6) | (2,084.8) |
| Total stockholders’ equity | 2,956.9 | 2,746.0 |
| Total liabilities and stockholders’ equity | $6,633.3 | $6,339.9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.